Windtree Therapeutics announces new istaroxime patent filing

Windtree Therapeutics (WINT) announced that it has filed a new istaroxime PCT patent application entitled, “ISTAROXIME DERIVATIVES THEREOF FOR PREVENTING OR REDUCING THE RISK OF ACUTE MYOCARDIAL ARRHYTHMIA.” The patent filing expands upon data obtained from animal model testing and the istaroxime human clinical trials in acute heart failure and early cardiogenic shock, including the latest positive Phase 2b istaroxime study in ECS patients. Istaroxime has also shown beneficial effects in rat studies with ischemia-reperfusion induced arrhythmias. Istaroxime-metabolite derivatives have shown superior properties in these models indicating their potential as promising therapeutics for the treatment of patients with ischemia needing improvement in cardiac function.